Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: vervetx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 4/8/2024 | $15.00 | Buy | H.C. Wainwright |
| 4/13/2023 | $29.00 | Buy | Canaccord Genuity |
| 2/1/2023 | $21.00 | Neutral | Cantor Fitzgerald |
| 12/15/2022 | $13.00 | Sell | Goldman |
| 10/6/2022 | $48.00 | Neutral | Credit Suisse |
| 8/25/2022 | $32.00 → $56.00 | Hold → Buy | Stifel |
| 6/17/2022 | $48.00 | Outperform | BMO Capital Markets |
| 2/18/2022 | $42.00 | Outperform | RBC Capital |
| 9/24/2021 | $58.00 | Hold | Stifel |
SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)
SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketable securities of approximately $500 million; cash runway into mid-2027 BOSTON , May 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic med
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 134,860 shares of the company's common stock and an aggregate of 65,398 restricted stock units (RSUs). The options have an exercise price of $5.67 per share, which is equa
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company's novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Hea
BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 50,700 shares of the company's common stock and an aggregate of 17,800 restricted stock units (RSUs). The options have an exercise price of $4.57 per share, which is equa
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C). "The IND clearance from the U.S. F
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 14,300 shares of the company's common stock and an aggregate of 20,100 restricted stock units (RSUs). The options have an exercise price of $6.33 per share, which is eq
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102 has been well-tolerated, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed Delivery of opt-in package to Eli Lilly and an opt-in decision from Lilly expected in the second half of 2025 Enrollment ongoing in Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 Cash, cash equivalents, and marketable securities of $524.3 million; cash runway into mid-2027 BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- V
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 34,320 shares of the company's common stock and an aggregate of 48,540 restricted stock units (RSUs). The options have an exercise price of $7.61 per share, which is equ
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
4 - Verve Therapeutics, Inc. (0001840574) (Issuer)
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th
LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear
EFFECT - Verve Therapeutics, Inc. (0001840574) (Filer)
10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)
8-K - Verve Therapeutics, Inc. (0001840574) (Filer)
SCHEDULE 13G - Verve Therapeutics, Inc. (0001840574) (Subject)
DEFA14A - Verve Therapeutics, Inc. (0001840574) (Filer)
DEF 14A - Verve Therapeutics, Inc. (0001840574) (Filer)
8-K - Verve Therapeutics, Inc. (0001840574) (Filer)
POS AM - Verve Therapeutics, Inc. (0001840574) (Filer)
S-8 - Verve Therapeutics, Inc. (0001840574) (Filer)
10-K - Verve Therapeutics, Inc. (0001840574) (Filer)
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (NASDAQ:VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations. "Allison joins Verve at an exciting stage of our company's evolution, on the heels of a successful IPO earlier this year and recent preclinical data updates from our lead programs targeting PCSK9 and ANGPTL3 as base editing
Cantor Fitzgerald upgraded Verve Therapeutics from Neutral to Overweight
H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00
Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00
Cantor Fitzgerald initiated coverage of Verve Therapeutics with a rating of Neutral and set a new price target of $21.00
Goldman initiated coverage of Verve Therapeutics with a rating of Sell and set a new price target of $13.00
Credit Suisse initiated coverage of Verve Therapeutics with a rating of Neutral and set a new price target of $48.00
Stifel upgraded Verve Therapeutics from Hold to Buy and set a new price target of $56.00 from $32.00 previously
BMO Capital Markets initiated coverage of Verve Therapeutics with a rating of Outperform and set a new price target of $48.00
RBC Capital initiated coverage of Verve Therapeutics with a rating of Outperform and set a new price target of $42.00
Stifel initiated coverage of Verve Therapeutics with a rating of Hold and set a new price target of $58.00